Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

rPPG

EU flag

EU proposes reforms to make first-in-human trials safer

New guideline revision paper “takes into account lessons learnt” from fatal Bial trial

Biogen Idec building

Biogen’s CEO Scangos to step down

Departure comes as multiple sclerosis drug Tecfidera achieves improved sales growth

- PMLiVE

Astellas promotes John Demaree

He becomes vice president of oncology marketing, Americas

- PMLiVE

Gilead’s universal hep C therapy Epclusa approved in EU

European nod for first pan-genotypic treatment follows recent FDA licensing

- PMLiVE

Ireland ekes out major savings in drug pricing deal

Four-year pharma agreement will save an estimated €600m

Roche Basel Switzerland

Roche says Tecentriq “off to a good start”

Bladder cancer therapy drug seems set for rapid growth

National Institute for Health and Care Excellence NICE logo

NICE backs PTC’s muscular dystrophy drug Translarna

Drug to be available on the NHS for DMD patients aged five and over

Dr Stephen Hoffman joins Bicycle Therapeutics

He becomes chairman of the board

Lucid Group take time out for work and play at their annual Summer Meeting

Lucid Group may be an award-winning medical education agency, packed with industry-leading talent, but it still understands how important it is to provide the best customer experience possible. 2015 was an...

Lucid Group Communications Limited

- PMLiVE

EU clears AZ’s FDA-rejected diabetes combination

Approval of two-drug therapy Qtern presents first-to-market advantage in Europe

Celgene building

Jounce bags $225m upfront in Celgene immuno-oncology deal

Five pipeline candidate agreement worth up to $2.5bn should Celgene claim the rights

Are you getting these benefits from your digital technology?

Your organisation switched from ‘paper to glass’, buying the latest mobile devices and hiring digital agencies to fill them with eye-catching content. But what happened?

Anthill Agency

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links